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ScienceDirectHigh-risk human papillomaviruses infect the basal cells of
human epithelia. There it deploys several mechanisms to
suppress pathogen receptor recognition signalling, impeding
the immune system to control viral infection. Furthermore,
infected cells become more resistant to type I and II interferon,
tumour necrosis factor-a and CD40 activation, via interference
with downstream programs halting viral replication or
regulating the proliferation and cell death. Consequently, some
infected individuals fail to raise early protein-specific T-cell
responses that are strong enough to protect against virus-
induced premalignant disease and ultimately cancer.
Therapeutic vaccines triggering a strong T-cell response
against the early proteins can successfully be used to treat
patients at the premalignant stage but combinations of different
treatment modalities are required for cancer therapy.
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Introduction
Progressive infections show split immunity to HPV late
and early proteins
About 80% of sexually active individuals become infected
with a high-risk HPV type (hrHPV). While most hrHPV
infections (90%) are controlled within two years [1], viral
persistence may lead to malignancies. The hrHPV are
responsible for 5% of all human cancers. Of the 14 dif-
ferent hrHPV types detected in cervical carcinoma,
HPV16 and 18 are the most prevalent. HPV16 is the
dominant type in all other HPV-induced cancers [2,3].Current Opinion in Virology 2017, 23:16–22 HPV exclusively infect keratinocytes (KCs) in the basal
layer of the epidermis and mucosal epithelia, through
micro-wounds and abrasions. In the large majority of
exposed but healthy individuals strong type 1 (IFNg,
TNFa, IL-2 producing) T-cell responses to the structural
protein L1 as well as the early proteins E2, E6 and E7 are
detected [4–7]. Stimulation of the L1-specific immune
response most likely occurs via the uptake of virions,
produced during the productive phase of the infection, by
the Langerhans cells that reside in the epidermis. T-cell
responses to L1 are detected in healthy individuals and in
patients with premalignant lesions or cancer [7]. While
they reflect a productive infection, they do not contribute
to the control of viral infection as L1 is not expressed in
the first few layers of the proliferating infected basal cells.
In these layers, however, the early proteins E2, E6 and E7
are produced and immunity may be induced if these
proteins are taken up by professional antigen presenting
cells. However, type 1 T-cell responses to the early
proteins are weak at best in patients with persistent
infections.
The HPV infected skin expresses the cytosolic DNA
sensors STING, AIM2 and IFI16. HPV DNA can trigger
the latter two resulting in the secretion of IL-1b and IL-
18 [8]. These cytokines mediate local and systemic
immune responses to infection [9] and might be critical
for early immune control of virus replication [10–12].
Hence, there is a period in which an HPV infection
may trigger a protective T-cell response, dominated by
CD4+ T-cells [5,6,12,13,14], but if this response is too
weak or too late HPV may deploy several mechanisms to
suppress the pathogen recognition receptor pathways
[15–19,20,21–23]. Importantly, as HPV infection does
not cause viremia or cell lysis, either intact immune
signalling or minor trauma to the lesion [24] is crucial
to induce protective immunity.
Mechanisms used by HPV to prevent immune control
Basal KCs express several pattern-recognition receptors
(PRR) that can recognize viral DNA or RNA (Figure 1).
PRR ligation results in the production of type I interferon
and pro-inflammatory cytokine production through sig-
naling via interferon regulatory factor (IRF) and nuclear
factor of kappa-light-chain-enhancer of activated B cells
(NFkB) activating pathways. Several genome-wide tran-
scription studies reported that hrHPV types have found
means to suppress PRR- and type I IFN-induced signal-
ing pathways [22]. Recently it was found that the cells in
hrHPV-positive low-grade lesions display higher levels ofwww.sciencedirect.com
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High-risk human papillomavirus deploys countermeasures to prevent immune control.
High-risk HPV can infect basal keratinocytes. The virus can be recognized by the pattern recognition receptors for viral DNA: IFI16, AIM2, TLR9
and for viral RNA: TLR-3, RIG-I, MDA-5. Most of these will activate interferon production via TRAF3-TBK1-IKKe-IRF3 interactions but this is
prevented by downregulation of STING and the upregulation of UCHL1, which inactivates TRAF3 via deubiquitination. UCHL1 also suppresses
TLR9 and TLR3/RIG-I/MDA5-mediated activation of NFkB via interaction with TRAF6 and degradation of NEMO. While viral DNA may activate the
formation of the AIM2 inflammasome, required to cleave pro-IL1b into the potent immune activating cytokine IL-1b, the upregulation of E6-AP
results in the ubiquitination of pro-IL1b targeting it for proteasomal degradation. Activated CD4+ type 1 T cells express CD40L and produce IFNg
and TNFa. Activation of CD40 and the IFNg receptor (IFNR) result in proliferative arrest of cells, but this is impaired by the downregulation of
STAT1 and IFITM1 (downstream of IFNR) and deactivation of TRAF3 (downstream of CD40) by UCHL1, with as result less upregulation of the
antiproliferative gene RARRES1. RIPK3 is one of the key components in necroptosis, which is down-regulated by hrHPV, resulting in reduced IFNg
and TNFa induced necroptosis. High-risk HPV induces the overexpression of epidermal growth factor receptors (EGFR) and this increases the
expression of IFRD1. IFRD1 mediates RelA K310 deacetylation thereby attenuating the transcriptional activity of NFkB. The resistance will be
similar to CD8+ T-cell produced IFNg and TNFa. Black arrows indicate the normal reactivity in the cell after stimulation. The purple proteins are
upregulated and orange proteins are downregulated as a result of hrHPV infection.E2 than normal hrHPV-infected cells, and this coincided
with downregulation of STING [20]. Furthermore,
hrHPV upregulated UCHL1, a deubiquitinase which
was shown to inactivate TRAF3 and mediates the degra-
dation of NEMO [15] and it may inhibit TLR9www.sciencedirect.com expression [25]. Notably, prednisolone- and hydroxy-
chloroquine-mediated downregulation of TLR7 and
TLR9, respectively, is associated with HPV infections
[26]. As a consequence, persistently hrHPV-infected
cells will be less equipped to attract and activate theCurrent Opinion in Virology 2017, 23:16–22
18 Preventive and therapeutic vaccinesadaptive immune response via the production of inter-
ferons and cytokines (Figure 1). Especially, the secretion
of the potent immune activating cytokine IL-1b is
suppressed by hrHPV by targeting pro-IL-1b for
destruction [27].
However, even when the immune system manages to
mount a type 1 T-cell response it will be difficult for
these T cells to control a persistent infection as hrHPV
adapts the infected cells to become less sensitive to
immune control mechanisms (Figure 1). The virus inter-
feres with T-cell recognition via the reduction of MHC
class I and II expression but also by affecting the
downstream signalling pathways of CD40, and the
TNFa and IFNg receptors which normally will mitigate
the infection by arresting cell proliferation and inducing
cell death, but will also lead to amplification of the local
immune response via the direct (CD40, TNFa) and
indirect (IFNg) activation of NFkB (Figure 1). Persis-
tently hrHPV infected cells display lower levels of
STAT1 but this does not completely impair signalling
[28,29]. Therefore, hrHPV also downregulate the
interferon-induced transmembrane protein 1 (IFITM1)
thereby preventing the upregulation of the antiprolifera-
tive gene RARRES1 [29]. A similar suppression of
RARRES upregulation is noted after CD40 ligation
[30]. In addition, hrHPV evades TNFa-induced cell
death of infected cells by the downregulation of RIPK3,
a crucial regulator of necroptosis [29]. Local amplifica-
tion of immunity by the secretion of cytokines and the
attraction of immune cells is dampened by hrHPV
through an increased expression of interferon-related
developmental regulator 1 (IFRD1), which attenuates
the transcriptional activity of NFkB via deacetylation of
RelA [31] as well as by interfering with downstream
signalling of CD40, probably via the interaction of
UCHL1 and TRAF6 [15,30]. Finally, there is evidence
that hrHPV-infected cells create a local immune sup-
pressive microenvironment by altering the phenotype
and function of local antigen dendritic cells [32] and the
attraction of mast cells [33].
A strong vaccine-induced type 1 T-cell response regains
control of HPV-induced diseases
Therapeutic vaccines aim to stimulate strong type 1
helper T-cell and cytotoxic T-cell responses (Th1/CTL)
to attack infected cells. They come in many flavours [34]
and are also developed to treat HPV-induced diseases
[35].
Clinical success has been obtained in women either with
infected cells or with hrHPV-induced high-grade lesions.
GTL001 in combination with the TLR7 agonist imiqui-
mod topically applied to the vaccine site as adjuvant,
stimulated E7-reactivity and a post-hoc analysis sug-
gested increased and sustained clearance of HPV, albeit
that the group size was small [36].Current Opinion in Virology 2017, 23:16–22 Four different types of vaccines were tested for their
capacity to treat hrHPV-associated high-grade cervical
lesions (CIN2-3). The DNA vaccine VGX-3100 was
shown to induce strong E6/E7-specific Th1/CTL
responses [37] and was subsequently tested in a large
randomized placebo-controlled trial [38]. The sponta-
neous clearance rate of CIN2-3 was 30% and this was
increased to 50% by vaccination. Post-hoc analyses
revealed a relation between a clinical response and
the strength of the vaccine-induced  immune response
[38]. Also the DNA vaccine GX-188E induced E6/E7-
specific Th1/CTL responses that resulted in viral con-
trol and lesion regression in 7 out of 9 patients [39] while
another (pnGVL4a-CRT/E7 DNA) failed to induce
strong Th1/CTL reactivity or clinical reactivity exceed-
ing the spontaneous clearance rate [40]. GLBL101c, an
orally administered bacterial vector vaccine expressing
HPV16 E7 protein [41] did not lead to overt systemic
immunity but HPV-specific T-cells were detected in the
cervix. A downgrade of disease stage was found in 5 of
13 patients [41], just above the spontaneous clearance
rate. Similarly, PepCan, an HPV16 E6 peptide-based
vaccine with Candida skin test reagents as adjuvants
induced T-cell reactivity in <50% of the subjects and
there was no relation between immunity and lesion
regression or an increase in clearance rate [42,43].
The spontaneous clearance of HPV16-induced high-
grade lesions of the vulva is less than 1.5% and treat-
ment with the synthetic long peptide vaccine ISA101
considerably increased this percentage to more than
50% as shown in two subsequent medium-sized trials
[44,45]. Clinical reactivity was strongly related to the
strength of the vaccine-induced Th1/CTL response as
found during the post-hoc analyses of the first trial
[44,46] and confirmed as pre-defined marker in the
second trial [45].
The general observation from these trials is that if a strong
Th1/CTL response is evoked one has the best chance for
a clinical response. This fits with studies showing that
hrHPV increases the resistance of infected cells to the
effects of type 1 cytokine mediated signals but does not
make them insensitive [15,23–25,29,31,42]. In addi-
tion, it should be appreciated that the viral gene expres-
sion changes during the progression of disease and this
may impact on the immune evasive strategies deployed
[22]. For example, STING expression is regained in
progressive lesions, consistent with the loss of E2 protein
expression [23].
Currently 20 different ongoing trials focus on the treat-
ment of premalignant or cancerous lesions (Table 1).
Bearing in mind that local immune suppression hampers
the efficacy of therapeutic vaccines [34] there are a
couple of trials attracting the attention. Two trials try
to circumvent general immune suppression by vaccinat-
ing patients during cancer surgery or after successfulwww.sciencedirect.com
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Table 1
Current therapeutic vaccine trials
Vaccine Goal Disease stage Status NCT#
PDS0101 Safety, tolerability and pharmacodynamics of




VB10.16 Safety and immunogenicity of an HPV16 E6&E7 DNA vaccine
targeted to antigen presenting cells
CIN2-3 Not recruiting 02529930
pnGVL4a-CRT/E7 DNA
& topical imiquimod
Safety and efficacy of intralesional administration and





Safety and efficacy of vaccination with Imiquimod treatment of
lesion
CIN3 Recruiting 00788164
PepCan Efficacy and safety of HPV16 E6 peptides & Candin adjuvant CIN2-3 Recruiting 02481414
GX-188E Determine recurrence of CIN and evaluation of long-term safety CIN3 Recruiting 02411019
ISA101 & IFNa
as immune modulator
Safety, immunogenicity and efficacy of different intradermal
doses HPV16 E6 and E7 synthetic long peptides with or without
pegylated IFNa
AIN2-3 Recruiting 01923116







Immunogenicity and efficacy of vaccination Advanced or
recurrent cancer
Completed 00019110
ADXS11 Immunogenicity and impact on 1 year survival of live-attenuated











INO-3112 Safety and immunogenicity of VGX-3100 plus DNA-based




INO-3112 Safety and immunogenicity when delivered by electroporation Head and neck
cancer
Not recruiting 02163057
ADXS11 Immunogenicity and toxicity of live-attenuated Listeria




ISA201 Biological activity of two HPV16 E6 specific peptides coupled to

















Safety and immunogenicity of different doses HPV16 E6&E7
long peptides with or without pegylated IFNa as combination







Safety and efficacy of a single HLA-A2-restricted HPV16 E7
epitope with metronomic cyclophosphamide
HPV-induced
cancers
















Not yet open 02405221standard treatment, aiming to prevent recurrences
(NCT00002916; NCT02405221). In three trials vaccina-
tion is combined with chemotherapeutics that may allevi-
ate immune suppression mediated by regulatory T cells
(NCT02865135) or myeloid cells (NCT 02526316;
NCT02128126) [47,48]. Last but not least, activated T
cells may express PD-1, which after engagement with PD-
L1 on tumor cells or myeloid cells, suppresses their effector
function. In one trial this is prevented by combining
vaccination with the PD-1 blocking antibody nivolumab
(NCT02426892).www.sciencedirect.com Conclusion
The high incidence of HPV infections, the quick clear-
ance of infections in spite of HPV’s stealthy behaviour,
and the detection of early protein-specific T cells in most
healthy subjects while seroconversion is low, indicates
that in general pathogen recognition of hrHPV occurs
after which a protective T-cell response is launched. The
production of IL-1b may be crucial for the activation of a
strong T-cell response during hrHPV infection. IL-1b is
important for the acute phase response and it also
enhances the expansion, differentiation and tissueCurrent Opinion in Virology 2017, 23:16–22
20 Preventive and therapeutic vaccineslocalization of CD4+ and CD8+ T-cell responses [49,50].
However, polymorphisms in the IL-1 gene [12,51] and
active downregulation of a network of IL-1b intercon-
nected genes by hrHPV [16] as well as inhibition of IL-1b
secretion at higher stages of disease [27] may stifle the
development of protective type 1 T-cell responses in a
minority of cases, with weak T-cell reactivity as result. In
addition, hrHPV lowers the sensitivity of infected cells to
key type 1 cytokines which otherwise will help infected
cells to control the virus and it creates a local suppressive
environment. This raises the bar for the type 1 T-cell
responses to gain control of infection but therapeutic
vaccines can stimulate type 1 HPV-specific T cell
responses with a magnitude that readily exceeds the
weak responses in patients and this is associated with
regained control of hrHPV infection. In time, however,
additional layers of immune suppression develop within
the hrHPV-induced lesion necessitating combinations of
vaccines with other treatment modalities to alleviate
these suppressive mechanisms.
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